Progress in immunotherapy for small cell lung cancer

Table 1 Immune checkpoint inhibitors and relevant clinical studies

		Ref.	Method	PFS	OS	ORR (%)
Ipilimumab	CA184-156	[26]	Ipilimumab plus Etoposide and Platinum vs Placebo plus Etoposide and Platinum	4.6 mo vs 4.4 mo	11.0 mo vs 10.9 mo	-
Nivolumab	CheckMate 032	[29]	(1) Nivolumab 3 mg/kg; (2) Ipilimumab 1 mg/kg + Nivolumab 1 mg/kg; (3) Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg; and (4) Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg	1.4 mo	5.6 mo	(1) 10; (2) 33; (3) 23; and (4) 19
	CheckMate 451	[31]	Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg q3w vs Nivolumab 240 mg q2w vs Placebo	-	9.2 mo vs 10.4 mo vs 9.6 mo	-
	CheckMate 331	[32]	Nivolumab 240 mg q2w vs Topotecan	-	7.5 mo vs 8.4 mo	13.7 vs 16.5
Pembrolizumab	KEYNOTE-158	[33]	Pembrolizumab 200 mg q3w	2 mo	9.1 mo	18.7
Atezolizumab	IMpower-133	[37]	Atezolizumab + Etoposide and Carboplatin vs Placebo + Etoposide and Carboplatin	5.2 mo vs 4.3 mo	12.3 mo vs 10.3 mo	-
Durvalumab	CASPIAN	[40]	Durvalumab plus Etoposide and Platinum vs Etoposide and Platinum	5.1 mo vs 5.4 mo	13.0 mo vs 10.3 mo	-

PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate.